Topical nepafenec in eyes with noncentral diabetic macular edema

Retina

Volumn 35, Issue 5, 2015, Pages 944-956

  Friedman, Scott M ^a   Almukhtar, Talat H ^b   Baker, Carl W ^c   Glassman, Adam R ^b   Elman, Michael J ^d   Bressler, Neil M ^e   Maker, Manvi P ^f   Jampol, Lee M ^g   Melia, Michele ^b  

^a Florida Retina Consultants   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c Paducah Retinal Center   (United States)

^d Elman Retina Group PA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetic Retinopathy Clinical Research Network; nepafenac; noncentral DME; topical NSAID

Indexed keywords

NEPAFENAC; PLACEBO; BENZENEACETAMIDE DERIVATIVE; EYE DROPS; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLACETIC ACID DERIVATIVE;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BASAL CELL CARCINOMA; BLEPHARITIS; BLURRED VISION; CATARACT EXTRACTION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIPLOPIA; DRUG SAFETY; DRY EYE; EPIPHORA; EYE BURN; EYE DISCHARGE; EYE IRRITATION; EYE PAIN; EYELID PAIN; FEMALE; HUMAN; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOVASCULARIZATION (PATHOLOGY); NERVE PARALYSIS; NONCENTRAL DIABETIC MACULAR EDEMA; OCULAR PRURITUS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROLIFERATIVE DIABETIC RETINOPATHY; PRURITUS; PSEUDOEXFOLIATION; PTOSIS; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RETINAL THICKNESS; VIRAL CONJUNCTIVITIS; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; INSULIN DEPENDENT DIABETES MELLITUS; MACULAR EDEMA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHENYLACETATES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84929043837     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000403     Document Type: Article

References (20)

1. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54:1-32.
2. Arevalo JF. Diabetic macular edema: current management 2013. World J Diabetes 2013;4:231-233.
3. National Diabetes Fact Sheet. Available at: http://www.cdc. gov/diabetes/pubs/factsheet11.htm.
4. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-324.
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
6. AAO preferred practice patterns: diabetic retinopathy. Available at: http://one.aao.org/preferred-practice-pattern/diabeticretinopathy-ppp-september-2008-4th-print. Accessed February 27, 2014.
7. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110:1690-1696.
8. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-79.
9. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27:281-291.
10. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal antiinflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-133.
11. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol 2008;2:689-692.
12. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin 2006;22:397-404.
13. Nevanac. EPAR summary for the public. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000818/human-med-000928.jsp&mid=WC0b 01ac058001d124. Accessed February 27, 2014.
14. Chalam KV, Bressler SB, Edwards AR, et al. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 2012;53:8154-8161.
15. Diabetic Retinopathy Clinical Research Network Writing Committee. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol Published online July 24, 2014. doi:10.1001/jamaophthalmol.2014.169.
16. Almeida DR, Khan Z, Xing L, et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J Cataract Refract Surg 2012;38:1537-1543.
17. Miyake K, Ota I, Miyake G, et al. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. J Cataract Refract Surg 2011;37:1581-1588.
18. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 2012;6: 1259-1269.
19. Bressler NM, Edwards AR, Antoszyk AN, et al. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol 2008;145:894-901.
20. Maldonado RM, Vianna RN, Cardoso GP, et al. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res 2011;36:768-773.